AstraZeneca Crestor Defense Minimizes Risk Of High Dose, FDA Says
Executive Summary
An AstraZeneca newspaper ad defending the safety of Crestor improperly suggests that all doses of rosuvastatin are "just as safe" as other statins, FDA says in a Dec. 21 "untitled" letter to the company
You may also be interested in...
To Crestor’s Foe, FDA Says Toxicity Is Low, But DTC Ads Must Go
FDA says AstraZeneca's Crestor is as safe as, if not safer than, other statins for a given LDL-lowering efficacy, but its ad campaign cannot claim superiority to Pfizer's Lipitor
Crestor DTC Ads To Resume Following Safety Labeling Update
AstraZeneca will resume direct-to-consumer ads for Crestor following the completion of labeling revisions that emphasize an increased risk of rhabdomyolysis, especially at the statin's highest approved dose
Crestor DTC Ads To Resume Following Safety Labeling Update
AstraZeneca will resume direct-to-consumer ads for Crestor following the completion of labeling revisions that emphasize an increased risk of rhabdomyolysis, especially at the statin's highest approved dose